Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicifadine SCHEMBL10235464 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL38793 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520915 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520900 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL5436336 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL121607 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL5443365 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL1438038 | 0.96 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL26938717 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL30272554 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | claimed |
| EP-2016053-B1 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007127421-A2 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | BPHL, MYOF, NISCH | SLC6A2 625/4885SLC6A4 1813/4885SLC6A3 1420/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | SLC6A2 1776/4885SLC6A4 1519/4885SLC6A3 955/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | SLC6A2 14/4885SLC6A4 44/4885SLC6A3 2/4885 |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | ADH1C, AVPR1B, HTR1B | SLC6A2 463/4885SLC6A4 379/4885SLC6A3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.